H. Lundbeck (CPSE:HLUN B) - Cotización, noticias y análisis

Resumen de acción HLUN B

HLUN B fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	3/6
Financial Health	5/6
Dividends	3/6

Recompensas

Cotiza un 64% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 9.89%

Los beneficios aumentaron un 1.3% el pasado año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Historial de dividendos inestable

Competidores de H. Lundbeck A/S

ALK-Abelló

CPSE:ALK B

kr.31.4b

Novo Nordisk

CPSE:NOVO B

kr.4.4t

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

Aspen Pharmacare Holdings

JSE:APN

R102.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	kr.37.68
52 Week High	kr.39.82
52 Week Low	kr.30.96
Beta	0
1 Month Change	7.17%
3 Month Change	15.09%
1 Year Change	3.57%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	15.94%

Noticias y actualizaciones recientes

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

Recent updates

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Rentabilidad de los accionistas

	HLUN B	DK Pharmaceuticals	Mercado DK
7D	2.8%	2.3%	2.9%
1Y	3.6%	18.5%	37.4%

Rentabilidad vs. Industria: HLUN B obtuvo unos resultados inferiores a los del sector Danish Pharmaceuticals , que el año pasado arrojó un rendimiento del 8.7%.

Rentabilidad vs. Mercado: HLUN B obtuvo unos resultados inferiores a los del mercado Danish, que fueron del 36.8% el año pasado.

Volatilidad de los precios

Is HLUN B's price volatile compared to industry and market?
HLUN B volatility
HLUN B Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.8%
10% least volatile stocks in DK Market	2.9%

Precio estable de las acciones: HLUN B no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de HLUN B (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1915	5,681	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, empresa biofarmacéutica, se dedica a la investigación, desarrollo, producción y venta de productos farmacéuticos para el tratamiento de trastornos psiquiátricos y neurológicos en Europa, Estados Unidos e internacionalmente. Los principales productos de la empresa son Abilify Maintena/Abilify Maintena para la esquizofrenia y el trastorno bipolar I en adultos; Brintellix/Trintellix para el tratamiento de los trastornos depresivos; Northera para el tratamiento de la hipotensión ortostática neurógena sintomática; Vyepti para la prevención de la migraña; y Rexulti/Rxulti para el tratamiento del TDM y la esquizofrenia. También suministra Azilect para tratar la enfermedad de Parkinson; Cipralex/Lexapro para la depresión; Ebixa para tratar la demencia; Onfi para la epilepsia; Sabril para el tratamiento de las crisis parciales complejas refractarias y los espasmos infantiles; Xenazine para la corea; Deanxit para la depresión; Cipramil para la depresión y la ansiedad; y Cisordinol para tratar la psicosis.

Resumen de fundamentos de H. Lundbeck A/S

¿Cómo se comparan los beneficios e ingresos de H. Lundbeck con su capitalización de mercado?
Estadísticas fundamentales de HLUN B
Capitalización bursátil	kr.36.47b
Beneficios(TTM)	kr.2.42b
Ingresos (TTM)	kr.20.16b

15.5x

Ratio precio-beneficio (PE)

1.9x

Ratio precio-ventas (PS)

¿Está HLUN B sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HLUN B
Ingresos	kr.20.16b
Coste de los ingresos	kr.4.45b
Beneficio bruto	kr.15.70b
Otros gastos	kr.13.29b
Beneficios	kr.2.42b

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Aug 21, 2024

Beneficios por acción (BPA)	2.44
Margen bruto	77.91%
Margen de beneficio neto	11.99%
Ratio deuda/patrimonio	16.6%

¿Cómo se ha desempeñado HLUN B a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.9%

Rentabilidad actual por dividendo

29%

Ratio de pagos

Resumen de acción HLUN B

Recompensas

Análisis de riesgos

Competidores de H. Lundbeck A/S

CPSE:ALK B

kr.31.4b

CPSE:NOVO B

kr.4.4t

LSE:HIK

UK£4.4b

JSE:APN

R102.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Recent updates

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de H. Lundbeck A/S

15.5x

1.9x

Beneficios e Ingresos

Dividendos

1.9%

29%